Sprint Bioscience AB SPRINT

OMXSTO · Sweden · Health Technology

SEK 3.41-0.16 (-4.48%)

Market open· Oct 2, 2026, 7:48 AM UTC· SEK · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Sprint Bioscience AB SPRINT

OMXSTO · Sweden · Health Technology

SEK 3.41-0.16 (-4.48%)

Market open· Oct 2, 2026, 7:48 AM UTC· SEK · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

+36.40% · 6MFull-screen chart

Open SEK 3.46High SEK 3.57Low SEK 3.40Close SEK 3.41Volume 78.97K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: SEK 3.57
Day range: SEK 3.40 – SEK 3.57
52-week range: SEK 0.5640 – SEK 4.59
Volume: 76.33K
Market cap: SEK 358.75M
P/E (TTM): 4.0
Next earnings date: 2026-11-11
Avg. volume (1Y): 556.86K

Performance

1 week

+16.72%

1 month

+8.54%

3 months

-3.78%

6 months

+36.40%

Year to date

+138.93%

1 year

+518.06%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Pharmaceuticals: Major
Country: Sweden
Exchange: OMXSTO
Shares outstanding: 105.52M
Employees: 30
ISIN: SE0006343745
Beta: 0.46

Technical view

Above averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceJun 08, 2026

Greenland Resources And 2 Other European Penny Stocks To Consider

European markets have recently shown a mixed performance, with the pan-European STOXX Europe 600 Index experiencing a slight decline amid geopolitical uncertainties and economic challenges. Despite these market fluctuations, there remains an opportunity for investors to explore smaller or newer companies, often referred to as penny stocks. While the term "penny stock" might seem outdated, it still represents a sector where companies with strong financials can offer substantial value and...

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.